2 Drug Stocks To Consider In The Coming Days

Wed, 06/27/2012 - 17:52 EDT - Seeking Alpha

By Matt Schilling:The FDA approved the first obesity drug in 13 years on Wednesday, and shares of Arena Pharmaceuticals (ARNA) had been trading up as much as 40%. According to the LA Times, "a clinical trial of lorcaserin published in the New England Journal of Medicine found that two-thirds of patients on the drug lost 5% of their body weight, while a third lost at least 10%, after one year taking the drug as a supplement to diet and exercise." That wasn't the only good news hitting the pharmaceutical wires today. In my opinion, not only does Arena look fantastic at these levels, but two other drug companies have caught my eye and carry some very nice upside potential.Supernus Pharmaceuticals (SUPN), which trades in a 52-week range of $4.30 (52-week low) to $15.09 (52-week high), was trading as high as $15.15/share on Wednesday. Shares were up roughly 17% at one pointComplete Story »

Original article
Login or register to post comments

2 Stocks That I Believe Have Strong Upside Potential
By Matt Schilling:Shares of Arena Pharmaceuticals (ARNA) were trading up as much as 40% on Wednesday, as the FDA approved it first obesity drug in 13 years. The drug, Lorcaserin (aka Belviq), eliminates ones desire to eat, even at times when they aren't hungry, which essentially eliminates one's desire to snack. That being said, it wasn't the only good news hitting the wires today.
3 Pharmaceutical Stocks I'm Looking At This Tuesday
By Matt Schilling:Clinical Trials and FDA Recommendations play vital roles in the life expectancy of drug companies. They also happen to be the two key variables I use when considering small-cap pharmaceutical stocks. That being said, two of the three companies reacted positively to news regarding the notion of regulatory approval and the third reacted negatively to the news that the company was suspending Phase II trials of its bone and cartilage cancer drug.
Drug Approvals Are Priced In, Wait For The Buying Opportunity
By Rx Stocks:On, Friday (Dec 21, 2012), two drugs were approved. Adusive was approved, and Alexza (ALXA) shares dropped significantly (10%) in after hours trading. Gattex was approved, and NPS pharmaceuticals (NPSP) share price fluctuated briefly, but remained basically unchanged on the day.
Friday's Bio Pharma Watch List: Focus On Arena And Antares
By Scott Matusow:These 2 Bio Pharmas should be watched closely for today's trading session and weeks to come. I will do my best using the charts and offer fundamental factors why I feel these stocks could see a nice short term gain, and could see larger mid to long term gains.Arena Pharma (ARNA) 2/26/12 pps: $2.15
Hedge Arena Pharmaceuticals With An Options Collar
By Helix Investment Management:In the biotechnology sector, the market often chooses to focuses on a particular disease targeted for treatment, such as cancer, or hepatitis C. In addition to those diseases, there is currently a very sharp focus on obesity treatments.
Risk Vs. Reward: 2 Biotech Stocks I'm Considering In The Wake Of Recent Developments
By Matt Schilling:Clinical trials and FDA recommendations play vital roles in the life expectancy of drug companies. They also happen to be the two key variables I use when considering small-cap pharmaceutical stocks. That being said, the two biotech companies featured have reacted positively to recent news regarding clinical trial development.
Arena Pharmaceuticals Weight Loss Drug Lorcasersin Approved By The FDA
By Scott Matusow:Arena Pharma (ARNA) a short while ago received FDA approval for the weight-loss drug Lorcaserin.
Arena Pharmaceuticals Inc. (ARNA) Shares Rise On Study
Shares of diet-drug developer Arena Pharmaceuticals Inc. (ARNA) jumped 22 percent Thursday, the most intraday since June 2009.
Appetite For Arena Stock May Increase Ahead Of Obesity Drug NDA Re-Submission
By M.E. Garza: We anticipate that shares of Arena Pharmaceuticals (ARNA) will continue to creep up after Analysts at Piper Jaffray have upgraded the firm and raised the share price target from $1.50 to $3.
Is Arena's Lorcaserin On Track For Approval In 2012?
By KLLJ Investments: Arena Pharmaceuticals (ARNA) investors have had a tough road over the last 12 months since a negative vote by an Advisory Committee called to review Arena’s lead drug candidate for the treatment of obesity – lorcaserin. The stock was trading close to $7.00 a year ago heading into that fateful Advisory Committee, down to under $2 after a negative vote foreshadowed a Complete Response Le

Main menu

Secondary menu

2 Drug Stocks To Consider In The Coming Days

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu